Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Plans Lotronex Randomized Withdrawal Study If Drug Is Reintroduced

Executive Summary

GlaxoSmithKline has committed to a randomized withdrawal study for Lotronex if the irritable bowel syndrome agent is allowed back onto the market

You may also be interested in...



GSK Lotronex Risk Management Program Allows For Off-Label Use

GlaxoSmithKline will track prescriptions for Lotronex to gauge use of the irritable bowel syndrome therapy outside of the risk management program

GSK Lotronex Risk Management Program Allows For Off-Label Use

GlaxoSmithKline will track prescriptions for Lotronex to gauge use of the irritable bowel syndrome therapy outside of the risk management program

GSK Lotronex Plan Follows Accutane Model; Relaunch “Months” Away

GlaxoSmithKline's Lotronex risk management program will follow the Accutane model

Related Content

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel